141106-46-9

Upstream product

• 141106-45-8 4-<3-(4-fluorophenyl)phenoxy>butanoic acid 
• 10540-41-7 4'-fluoro-[1,1'-biphenyl]-3-ol 

Downstream Products

• 748102-38-7 [8-(4-Fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]oxepin-5-yl]-(1-methyl-heptyl)-amine 
• 170639-07-3 [8-(4-Fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]oxepin-5-yl]-hexyl-amine 
• 141106-48-1 (+/-)-N-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N₁-n-heptylamine 
• 170639-10-8 [8-(4-Fluoro-phenyl)-2,3,4,5-tetrahydro-benzo[b]oxepin-5-yl]-(4-propoxy-butyl)-amine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of new ACAT inhibitors

A series of heterocyclic ureas were synthesized and their ability to inhibit arterial and intestinal ACAT was assessed in animals.The structural modifications carried out in this series led to N2-(2,4-difluorophenyl)-N1-8-(4-fluorophenyl)-2,3,4,5-tetrahydro-1-benzoxepin-5-yl-N1-n-heptylurea 21, which proved to be very active on both the inhibition of aortic ACAT and the inhibition of rat cholesterol intestinal absorption, thus exhibiting a strong hypocholesterolemic effect po in rat (ED25 = 0.2 mg/kg). aortic ACAT / intestinal inhibition / benzoxepin / urea / cholesterol / hypocholesterolaemic activity